Latest Period
Q2 2026
Security Snapshot
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) Institutional Ownership
CUSIP: 690469101
13F Institutional Holders and Ownership History from Q2 2017 to Q2 2026
Institutions Reporting
129
Shares (Excl. Options)
147,000,742
Price
$2.69
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- OVID on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 147,000,742
- Total 13F value
- $395,504,576
- Portfolio coverage rank
- 0%
- Share change
- +31,884,678
- Value change
- +$88,183,470
- Number of holders
- 129
- Shares outstanding
- 187,450,569
- SEC-reported price per share
- $2.33
- Insider filing price
- $2.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 690469101.
- 129 institutions reported positions in Q2 2026.
- 14 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 103 to 129 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $233,184,546 to $395,504,576.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 129 institutions filings for Q2 2026.
Security key
690469101
Latest holder period
Q2 2026
13F holders
129
13D/G owners
14
CIK / CUSIP context first
Open Q2 2026 holders
OVID full holder history
Ovid Therapeutics Inc. SEC filings
Ovid Therapeutics Inc. company facts
Ovid Therapeutics Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 690469101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
14
Security
OVID
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $53,369,510 | +$17,170,433 | 19,549,271 | +47% | RA Capital Management, L.P. | 30 Jun 2026 |
| Sirenia Capital Management LP | 9.9% | $51,930,239 | 18,031,333 | Sirenia Capital Management LP | 31 Mar 2026 | |||
| Affinity Asset Advisors, LLC | 7.9% | -13% | $41,342,377 | -$1,342,494 | 15,143,728 | -3.1% | Affinity Asset Advisors, LLC | 30 Jun 2026 |
| EVENTIDE ASSET MANAGEMENT, LLC | 6.3% | -14% | $32,247,418 | -$2,624,447 | 11,812,241 | -7.5% | Eventide Asset Management, LLC | 30 Jun 2026 |
| BlackRock, Inc. | 5.8% | +195% | $29,112,988 | +$25,430,351 | 10,822,672 | +691% | BlackRock, Inc. | 30 Jun 2026 |
| ADAR1 Capital Management, LLC | 5.1% | -26% | $26,098,743 | +$752,969 | 9,559,979 | +3% | ADAR1 Capital Management, LLC | 30 Jun 2026 |
| BALYASNY ASSET MANAGEMENT L.P. | 5% | -6.8% | $25,425,421 | +$6,235,642 | 9,313,341 | +32% | BALYASNY ASSET MANAGEMENT L.P. | 30 Jun 2026 |
| TAKEDA PHARMACEUTICAL CO LTD | 12% | $11,680,055 | 8,781,996 | Takeda Pharmaceutical Company Limited | 08 Dec 2025 | |||
| LEVIN JEREMY M | 4.5% | $24,628,326 | 8,551,502 | Jeremy M. Levin | 31 Mar 2026 | |||
| FEDERATED HERMES, INC. | 4.2% | -30% | $17,099,137 | 7,737,166 | 0% | Federated Hermes, Inc. | 30 Jun 2026 | |
| JANUS HENDERSON GROUP PLC | 10% | $9,461,772 | 7,114,114 | JANUS HENDERSON GROUP PLC | 28 Nov 2025 | |||
| Madison Avenue Partners, LP | 4% | $969,800 | 2,852,352 | Madison Avenue Partners, LP | 31 Dec 2024 | |||
| Point72 Asset Management, L.P. | 1.3% | -76% | $5,483,356 | -$13,891,006 | 1,903,943 | -72% | Point72 Asset Management, L.P. | 31 Mar 2026 |
| Rubric Capital Management LP | 0.67% | $153,131 | 478,533 | Rubric Capital Management LP | 30 Jun 2025 |
As of 30 Jun 2026, 129 institutional investors reported holding 147,000,742 shares of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID). This represents 78% of the company’s total 187,450,569 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
72%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11% | 20,741,234 | 0% | 0.02% | $55,897,626 |
| EVENTIDE ASSET MANAGEMENT, LLC | 6.3% | 11,812,241 | +19% | 0.42% | $31,774,928 |
| BlackRock, Inc. | 5.8% | 10,823,480 | +606% | 0% | $29,115,162 |
| RA CAPITAL MANAGEMENT, L.P. | 5.6% | 10,500,968 | -2% | 0.25% | $28,247,604 |
| Affinity Asset Advisors, LLC | 5.4% | 10,144,562 | -4.6% | 1.3% | $27,288,872 |
| STATE STREET CORP | 4.2% | 7,900,765 | +1419% | 0% | $21,253,058 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.1% | 7,760,114 | +48% | 0% | $20,874,707 |
| ADAR1 Capital Management, LLC | 4% | 7,417,479 | +63% | 0.94% | $19,953,019 |
| Balyasny Asset Management L.P. | 3.6% | 6,719,076 | +21% | 0.03% | $18,074,314 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.3% | 6,163,781 | 0% | 0.02% | $16,580,571 |
| FEDERATED HERMES, INC. | 3.2% | 5,951,666 | +67% | 0.02% | $16,009,982 |
| BRAIDWELL LP | 3.2% | 5,919,464 | 0.59% | $15,923,358 | |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 4,072,653 | +209% | 0% | $10,957,549 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1.7% | 3,101,129 | +210% | 0.93% | $8,342,037 |
| STEMPOINT CAPITAL LP | 1.3% | 2,417,283 | 1.1% | $6,502,491 | |
| Ikarian Capital, LLC | 1.2% | 2,269,704 | -22% | 1% | $6,105,503 |
| Point72 Asset Management, L.P. | 1% | 1,945,727 | +47% | 0.01% | $5,234,006 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.72% | 1,353,000 | -17% | 0.52% | $3,639,570 |
| NORTHERN TRUST CORP | 0.66% | 1,246,139 | +389% | 0% | $3,352,114 |
| VANGUARD FIDUCIARY TRUST CO | 0.61% | 1,140,753 | +65% | 0% | $3,068,626 |
| Propel Bio Management, LLC | 0.6% | 1,115,538 | +21% | 1.6% | $3,000,797 |
| Rosalind Advisors, Inc. | 0.59% | 1,107,994 | 0% | 1.1% | $2,980,504 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.55% | 1,030,943 | 0% | $2,773,237 | |
| Sio Capital Management, LLC | 0.54% | 1,005,334 | -20% | 0.46% | $2,704,348 |
| Ensign Peak Advisors, Inc | 0.53% | 988,084 | 0% | $2,657,946 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
37
Latest
Q2 2026
Rows shown
1-25 of 37
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 147,000,742 | $395,504,576 | +$88,183,470 | $2.69 | 129 |
| 2026 Q1 | 105,065,946 | $233,184,546 | +$91,068,869 | $2.22 | 103 |
| 2025 Q4 | 61,768,473 | $100,169,419 | +$54,659,119 | $1.63 | 83 |
| 2025 Q3 | 36,211,271 | $47,075,130 | +$6,613,712 | $1.30 | 80 |
| 2025 Q2 | 35,963,686 | $11,861,338 | -$3,392,024 | $0.33 | 69 |
| 2025 Q1 | 46,399,305 | $14,469,971 | -$2,823,886 | $0.31 | 81 |
| 2024 Q4 | 47,565,663 | $44,391,185 | +$933,718 | $0.93 | 80 |
| 2024 Q3 | 46,326,650 | $54,661,169 | -$2,312,497 | $1.18 | 75 |
| 2024 Q2 | 46,022,725 | $35,395,023 | -$20,868,716 | $0.77 | 72 |
| 2024 Q1 | 50,111,416 | $152,838,625 | -$4,734,653 | $3.05 | 80 |
| 2023 Q4 | 51,658,816 | $166,339,097 | +$8,163,314 | $3.22 | 77 |
| 2023 Q3 | 42,343,665 | $162,598,117 | +$5,682,119 | $3.84 | 64 |
| 2023 Q2 | 41,007,449 | $134,502,613 | +$8,714,482 | $3.28 | 69 |
| 2023 Q1 | 38,694,424 | $99,783,463 | +$651,350 | $2.58 | 60 |
| 2022 Q4 | 38,559,195 | $71,717,529 | +$2,582,813 | $1.86 | 58 |
| 2022 Q3 | 35,588,862 | $65,480,293 | +$1,720,712 | $1.84 | 55 |
| 2022 Q2 | 34,628,854 | $74,450,307 | -$3,009,412 | $2.15 | 52 |
| 2022 Q1 | 35,130,112 | $110,307,198 | +$3,432,314 | $3.14 | 61 |
| 2021 Q4 | 34,014,426 | $109,179,202 | +$1,236,530 | $3.21 | 65 |
| 2021 Q3 | 33,589,442 | $112,862,212 | -$90,780 | $3.36 | 70 |
| 2021 Q2 | 33,366,478 | $130,460,427 | -$11,009,099 | $3.91 | 76 |
| 2021 Q1 | 36,251,183 | $145,725,613 | +$42,574,480 | $4.02 | 85 |
| 2020 Q4 | 27,412,279 | $63,321,129 | -$6,383,233 | $2.31 | 75 |
| 2020 Q3 | 25,114,493 | $144,162,828 | +$11,138,040 | $5.74 | 90 |
| 2020 Q2 | 21,848,899 | $161,034,711 | +$48,530,099 | $7.37 | 78 |